Circulating cell-free DNA
How to achieve high yields of cfDNA
Circulating cell free DNA (cfDNA) in body fluids is being used for non-invasive, real-time biomarker research and more. Yet detection is often challenged by its low levels, fragmentation and preanalytical variabilities introduced by sample collection, plasma preparation, and nucleic acid purification.
Revvity chemagic cfDNA isolation kits, together with dedicated chemagic instruments rely on patented chemagic technology using M-PVA Magnetic beads to ensure a high quality of nucleic acid purification. Comparable yields to manual spin column methods were obtained with efficient removal of contaminants and exclusion of cross-contamination. With automation, variabilities associated with multiple handling steps are reduced and sample integrity maintained with full sample tracking capabilities.
Benefits of automated cfDNA isolation with chemagic™ technology:
- Reliable and comparable yields to manual methods
- Fast, automated workflow with on-board lysis and no heating required
- Wide range of sample inputs applicable from 0.5 to 18 ml
- Full sample tracking with barcode reading and bidirectional LIMS communication capability
- Ability to isolate viral nucleic acids
- Suitable for fresh or frozen plasma/serum from EDTA, citrate or Streck® Cell-free DNA BCT® tubes
- Downstream compatibility with various assays - ddPCR, NGS, qPCR etc.
- Compatibility with other automated Revvity systems
For research use only. Not for use in diagnostic procedures.
Best practices in cfDNA purification
Discover here tips and tricks for optimizing your cfDNA extraction process, enabling maximum yield and purity while minimizing contamination and degradation. Whether you're new to cfDNA extraction or looking to refine your existing protocols, these strategies will help you overcome common obstacles and achieve more consistent, reliable results.
Discover here tips and tricks for optimizing your cfDNA extraction process, enabling maximum yield and purity while minimizing contamination and degradation. Whether you're new to cfDNA extraction or looking to refine your existing protocols, these strategies will help you overcome common obstacles and achieve more consistent, reliable results.
Manual magnetic-bead based cfDNA extraction
If you do not have a chemagic instrument but would like to benefit from the advantage of chemagic M-PVA Magnetic Bead technology, the manual chemagic cfDNA 5k kit is now available. Process up to 5 ml of sample and avoid spillages and clogs linked to spin column or vacuum-based systems with an easy magnetic bead-based protocol.
If you do not have a chemagic instrument but would like to benefit from the advantage of chemagic M-PVA Magnetic Bead technology, the manual chemagic cfDNA 5k kit is now available. Process up to 5 ml of sample and avoid spillages and clogs linked to spin column or vacuum-based systems with an easy magnetic bead-based protocol.
Protocol for cfDNA isolation from cerebrospinal fluid
Current approaches for isolating cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) lack standardization, creating challenges for clinical research applications. To address this gap, a customer developed an optimized cfDNA isolation protocol specifically designed for CSF specimens.
Current approaches for isolating cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) lack standardization, creating challenges for clinical research applications. To address this gap, a customer developed an optimized cfDNA isolation protocol specifically designed for CSF specimens.
ctDNA reference standards
Mimix™ reference standards are cell line-derived to closely mimic patient samples. For over a decade, Revvity has been producing reference standards in the format of ctDNA for the surveillance of minimal residual disease (MRD) tracked via liquid biopsy. Our reference standards are available with matched negative controls to suit assay requirements.
Mimix™ reference standards are cell line-derived to closely mimic patient samples. For over a decade, Revvity has been producing reference standards in the format of ctDNA for the surveillance of minimal residual disease (MRD) tracked via liquid biopsy. Our reference standards are available with matched negative controls to suit assay requirements.
Featured resources
Featured products
What our clients say about us
References:
- Kwon, HJ., Shin, S.H., Kim, H.H. et al. Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer. Sci Rep 13, 13502 (2023).
- Frank, M. S., Andersen, C. S. A., Ahlborn, L. B., Pallisgaard, N., Bodtger, U., & Gehl, J. Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer. Cancer Research Communications, 2022; 2(10), 1174–1187.
- Callesen LB, Hansen TF, Andersen RF, Pallisgaard N, Kramer S, Schlander S, Rafaelsen SR, Boysen AK, Jensen LH, Jakobsen A, Spindler KG. OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol. Acta Oncol. 2022 Sep;61(9):1152-1156.
- Kirchweger P, Kupferthaler A, Burghofer J, Webersinke G, Jukic E, Schwendinger S, Wundsam H, Biebl M, Petzer A, Rumpold H. Prediction of response to systemic treatment by kinetics of circulating tumor DNA in metastatic pancreatic cancer. Front Oncol. 2022 Aug 30;12:902177.
- Kirchweger P, Kupferthaler A, Burghofer J, Webersinke G, Jukic E, Schwendinger S, Weitzendorfer M, Petzer A, Függer R, Rumpold H, Wundsam H. Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage. Eur J Surg Oncol. 2022 May;48(5):1046-1053.
- Broholm M, Bojesen R, Gögenur M, Weinberger Rosen A, Watt S, Bulut M, Vogelsang R, Quist Jensen H, Orhan A, Bjerrum E, Søs Auður Andersen C, Pallisgaard N, Litman T, Troelsen JT, Gögenur I. Circulating Cell-Free DNA and Systemic Inflammatory Response after Self-Expandable Metal Stent for Malignant Bowel Obstruction. Archives of Microbiology and Immunology 6 (2022): 247-255.
- Lefèvre AC, Pallisgaard N, Kronborg C, Wind KL, Krag SRP, Spindler KG. The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus. Cancers (Basel). 2021 May 18;13(10):2451.
- Yu J, Cho E, Choi J, Lim JE, Lee J, Kang M, Sung HH, Jeong BC, Seo SI, Jeon SS, Lee HM, Jeon HG. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance. Investig Clin Urol. 2021 Mar;62(2):224-232.
- Moon SM, Kim JH, Kim SK, Kim S, Kwon HJ, Bae JS, Lee S, Lee HS, Choi MY, Jeon BH, Jeong BH, Lee K, Kim HK, Kim J, Um SW. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer. Anticancer Res. 2020 Jun;40(6):3435-3444.
- Song, Ho Hyun et al. “Optimization of a Protocol for Isolating Cell-free DNA From Cerebrospinal Fluid.” Annals of laboratory medicine vol. 44,3 (2024): 294-298.
